Vivek Reddy, MD is the Helmsley Trust Professor of Medicine at the Mount Sinai Fuster Heart Hospital in New York, and a Visiting Professor of Cardiology at Homolka Hospital in Prague, Czechia. He investigates advanced arrhythmia therapies – including catheter ablation for AFib and VT, and device therapies for stroke prevention and heart failure.

He conducted many “first-in-human” studies including the first cryoballoon ablation for atrial fibrillation in 2004, the first use of a force-sensing catheter for AF ablation, and the first pulsed field ablation catheter procedures for AF in 2017. He was also lead author on a seminal study, SMASH-VT (published in the New England Journal of Medicine) on the use of prophylactic catheter ablation to prevent shocks in patients receiving defibrillators. In 2012, he implanted the world’s first miniature leadless pacemaker, and in 2022, the world’s first dual-chamber leadless pacemaker (with Petr Neuzil). He has been instrumental in the development of mechanical approaches to stroke prevention in AF. He has been the principal investigator (or on the Steering Committees) of numerous multicenter clinical trials including PROTECT-AF, PREVAIL, ASAP-TOO, PRAGUE-17, OPTION, CATALYST, CHAMPION-AF, CAPTURE2, INTERCEPT, LEADLESS II, HEARTLIGHT, TOCCASTAR, ADVENT, Sphere Per-AF, FLOW-AF, ADVANTAGE-AF and PULSAR.

He has served as co-Director of the Annual Boston Atrial Fibrillation Symposium since 2005, and founded and Directs the Annual International Symposium on Ventricular Arrhythmias since 2006, as well as founded and Directs the PFA Live at HRS since 2024 (along with his colleague, Srinivas Dukkipati).